A real-world data analysis of acetylsalicylic acid in FDA Adverse Event Reporting System (FAERS) database

被引:5
|
作者
Zhao, Bin [1 ]
Zhang, Xiaohong [2 ]
Chen, Moliang [1 ]
Wang, Yan [3 ]
机构
[1] Xiamen Med Res Inst, Xiamen Hlth & Med Big Data Ctr, Xiamen, Fujian, Peoples R China
[2] Xiamen Univ, Hosp 909, Sch Med, Zhangzhou, Fujian, Peoples R China
[3] Peoples Hosp Jiuquan City, Med Reprod Ctr, Jiuquan, Gansu, Peoples R China
关键词
Acetylsalicylic acid; Aspirin; Real-world data analysis; Adverse event; Adverse drug reaction; ASPIRIN; CHEMOPREVENTION; PREVENTION;
D O I
10.1080/17425255.2023.2235267
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
BackgroundAcetylsalicylic acid (Aspirin), one of the oldest medicines, is widely used in various clinical fields. However, numerous adverse events (AEs) have been reported. In this study, we aimed to investigate adverse drug reactions (ADRs) of aspirin using real-worlddata from the US Food and Drug Administration Adverse Event Reporting System (FAERS) database.MethodsWe assessed the disproportionality of aspirin-related AEs by calculating measures such as reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagationneural network (BCPNN), and Gamma-Poisson Shrinker (GPS).ResultsOut of 7,510,564 casereports in the FAERS database, 18644 reports of aspirin as the 'primary suspected (PS)' AEs were recorded. Disproportionality analyses identified 493 aspirin-related preferred terms (PTs) across 25 organ systems. Notably, unexpected significant AEs such as pallor (p=5.66E-33), dependence (p=6.45E-67), and compartment syndrome (p=1.95E-28) were observed, which were not mentioned in the drug's instructions.ConclusionOur findings align with clinical observations, highlighting potential new and unexpected ADR signals associated with aspirin. Further prospective clinical studies are necessary to confirm and elucidate the relationship between aspirin and these ADRs. This study offers a fresh and unique perspective for studying drug-AEs.
引用
收藏
页码:381 / 387
页数:7
相关论文
共 50 条
  • [1] A real-world data analysis of tirzepatide in the FDA adverse event reporting system (FAERS) database
    Liu, Liyuan
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [2] A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database
    Yang, Haiyan
    Wan, Zheng
    Chen, Moliang
    Zhang, Xiaohong
    Cui, Wugeng
    Zhao, Bin
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2023, 19 (04) : 217 - 223
  • [3] A real-world disproportionality analysis of cyclosporine from the FDA Adverse Event Reporting System (FAERS) database
    Cui, Shichao
    Li, Li
    Liu, Wensheng
    Zhao, Bin
    Zhong, Xingming
    [J]. BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2024, 57
  • [4] A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database
    Zou, Fan
    Zhu, Chengyu
    Lou, Siyu
    Cui, Zhiwei
    Wang, Dan
    Ou, Yingyong
    Wang, Li
    Chen, Junyou
    Lan, Yuanbo
    [J]. FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [5] The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
    Caruso, I.
    Di Gioia, L.
    Di Molfetta, S.
    Caporusso, M.
    Cignarelli, A.
    Sorice, G. P.
    Laviola, L.
    Giorgino, F.
    [J]. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2024,
  • [6] Real-world pharmacovigilance analysis of galsulfase: a study based on the FDA adverse event reporting system (FAERS) database
    Li, Shangze
    Huang, Runcheng
    Meng, Yuanyuan
    Liu, Yijia
    Qian, Jiao
    Zou, Junjie
    Yang, Jun
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [7] A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib
    Peng, Ling
    Xiao, Kui
    Ottaviani, Silvia
    Stebbing, Justin
    Wang, Ying-Jie
    [J]. EXPERT OPINION ON DRUG SAFETY, 2020, 19 (11) : 1505 - 1511
  • [8] A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for denosumab
    He, Yue
    Zhang, Rong
    Shen, Huarui
    Liu, Yingqi
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [9] Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database
    Wang, Junwei
    Zhang, Aiwei
    Ye, Miaoyong
    Zhang, Cunming
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [10] A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for alpelisib
    Lin, Yu
    Zheng, Xinlei
    Chen, Yan
    Nian, Qichun
    Lin, Li
    Chen, Maohua
    [J]. HELIYON, 2024, 10 (06)